Inking the clinical research joint-venture gives JSS a partner in Europe with monitoring and project management experience. JSS has also bought some assets from the Canadian subsidiary of Venn as part of its push to become the leading contract research organisation (CRO) in the country.
“The joint venture arrangement was timely as part of the global growth strategy executed by JSS through targeted acquisitions and key strategic alliances”, John Sampalis, CEO, chief scientific officer and Founder of JSS, said.
After selling assets to JSS the Canadian subsidiary of Venn will stop operating independently in the country. Sanjay Machado, president of the subsidiary, will work for the joint-venture out of JSS’ offices in Montreal and Venn expects the arrangement to boost its North American strategy.
“Venn will better be able to pursue the North America market through its strategic alliance with JSS while having a more diversified portfolio of services for its European clients, given the science-based expertise of JSS”, Tony Richardson, CEO of Venn, said.
Closure of the Quebec, Canada operation leaves Venn with offices in Ireland, France, the Netherlands and Switzerland. Venn will use these offices to support JSS’ clients that want to run clinical trials in Europe.
“The welcome addition of Venn's strategic positioning in the European market and strengths in the area of monitoring and project management services will augmented the science-based services offered by JSS”, Sampalis said.